Collagenase dressing refers to the use of a topical enzyme ointment, most commonly clostridial collagenase (marketed in the United States as Santyl), applied to wounds and typically covered by a secondary dressing to keep the product in place and maintain a moist environment. The enzyme selectively breaks down the denatured collagen found in dead tissue without harming the living tissue underneath, making it one of the few FDA-approved options for enzymatic wound debridement. It is used across a range of chronic and acute wounds, from diabetic foot ulcers and pressure injuries to partial-thickness burns, and the evidence for its effectiveness varies depending on wound type and what you compare it against.
How the Enzyme Works
When tissue dies in a wound, the collagen that once gave it structure becomes denatured and forms a tough, leathery layer called eschar or a softer yellowish layer called slough. That dead tissue slows healing by blocking new cell growth and providing a surface where bacteria can thrive. Collagenase derived from Clostridium bacteria specifically targets this denatured collagen, breaking it into smaller fragments that can be wiped or rinsed away at dressing changes. The enzyme leaves healthy collagen and living tissue largely intact, which is why clinicians describe it as “selective” debridement.1PubMed. Collagenase Santyl ointment: a selective agent for wound debridement
Beyond simply clearing dead tissue, research in animal models suggests the enzyme does more than clean house. Clostridial collagenase has been shown to promote the migration and proliferation of the cells that build new blood vessels and new skin, with an efficiency more than double that of the body’s own collagenase.2PubMed Central. Collagenase Promotes the Cellular Responses to Injury and Wound Healing In Vivo Separate laboratory work found that the ointment shifts wound immune cells toward an anti-inflammatory state, increasing signals that calm inflammation and decreasing the ones that drive it. That shift may help wounds move out of the stuck inflammatory phase that keeps many chronic wounds from healing.
Practical Application and Cross-Hatching
Collagenase ointment is applied directly to the wound bed in a thin layer, roughly the thickness of a nickel, once or twice daily depending on the prescribing clinician’s judgment. It needs moisture to work, so the wound is typically covered with a secondary dressing that keeps things moist without drying the enzyme out.
Before applying the ointment, clinicians often perform a technique called cross-hatching. This involves using a scalpel blade to make shallow scores in the hard eschar covering the wound, creating channels that let the enzyme penetrate deeper into the dead tissue. While cross-hatching is the recommended procedure for collagenase application, studies in long-term care settings have noted it is frequently skipped in everyday practice, which can slow the debridement process.3Wounds. A Comparison of Collagenase to Hydrogel Dressings in Wound Debridement If you or someone you care for is using collagenase at home, asking the wound care provider about cross-hatching is worth doing, because the enzyme simply cannot work as well when it sits on top of a thick, unbroken crust.
Diabetic Foot Ulcers
Diabetic foot ulcers are among the most-studied wound types for collagenase dressings. In a randomized controlled trial comparing collagenase to standard selective debridement in diabetic foot ulcers, both groups saw wound improvement, but the collagenase group showed better progress toward healing over time, with decreasing wound area and improved response rates by the end of follow-up.4PubMed. Clinical and economic assessment of diabetic foot ulcer debridement with collagenase: results of a randomized controlled study A separate trial compared collagenase to a silver-containing wound product in diabetic foot ulcers. The collagenase group saw about a 62% reduction in wound area versus 40% for the silver group. Although that 22-percentage-point gap did not reach statistical significance, and the time to closure was similar between groups, ulcer infections were numerically less common in the collagenase group.5PubMed Central. Clinical Outcomes for Diabetic Foot Ulcers Treated with Clostridial Collagenase Ointment or with a Product Containing Silver
An economic analysis built on randomized trial data projected that diabetic foot ulcers treated with collagenase plus standard care had higher healing rates than standard care alone (roughly 89% versus 80% projected over a year) and accumulated about 25% more healed weeks over that year.6PubMed Central. Cost-effectiveness of clostridial collagenase ointment on wound closure in patients with diabetic foot ulcers For people managing diabetic wounds, those extra healed weeks can make a real difference in daily life and in the risk of complications like infection or amputation.
Pressure Injuries
Pressure injuries, sometimes still called pressure ulcers or bedsores, develop in people who spend long periods in bed or a wheelchair. The dead tissue that accumulates in these wounds needs to be removed before healing can begin, and collagenase is one of the most commonly used enzymatic agents for that job. A systematic review and meta-analysis examining enzymatic debridement across wound types found that the evidence supports using collagenase for pressure ulcers specifically, alongside its use in diabetic foot ulcers and burns.7PubMed Central. Enzymatic debridement with collagenase in wounds and ulcers: a systematic review and meta-analysis
In a head-to-head comparison with hydrocolloid dressings (a common moisture-retentive wound covering that promotes the body’s own slow breakdown of dead tissue), pressure ulcers treated with collagenase healed in about 10 weeks on average, compared to 14 weeks for the hydrocolloid group.8PubMed. Economic evaluation of collagenase-containing ointment and hydrocolloid dressing in the treatment of pressure ulcers That four-week difference matters in settings like nursing homes and hospitals, where every extra week with an open wound raises the risk of infection and adds cost.
Burns
Burn wounds present a different challenge. The dead tissue in a burn is often thick and adherent, and the traditional approach is surgical excision, which requires anesthesia and can cause blood loss. Collagenase offers a nonsurgical alternative, particularly for partial-thickness burns where the deepest skin layers are still viable. The enzyme breaks down the denatured collagen in burned tissue, and the loosened fragments are removed at dressing changes.9PubMed Central. The role of collagenase ointment in acute burns: a systematic review and meta-analysis
A study of 78 children with partial-thickness burns treated with collagenase found that the enzyme alone achieved complete eschar removal in about 63% of patients, reducing the overall need for surgery and blood transfusions. The study’s authors suggested collagenase should be considered as an initial treatment of choice for eschar removal in children with partial-thickness burns without infection.10PubMed. Enzymatic debridement of burn wound with collagenase in children with partial-thickness burns For pediatric patients especially, avoiding surgery when possible is a significant advantage.
That said, collagenase is not the fastest enzymatic debriding agent available for burns. In a porcine model comparing collagenase to a bromelain-enriched product (derived from pineapple stems), none of the collagenase-treated full-thickness burns had complete eschar removal even after 14 days, and only about a third of the deep partial-thickness burns were fully debrided by day 14. The bromelain product achieved complete removal of partial-thickness eschar in a single application.11Journal of Burn Care & Research. A Comparison of Topical Agents for Eschar Removal in a Porcine Model: Bromelain-enriched vs Traditional Collagenase Agents Bromelain-based products are gaining traction in burn care, and for thick, full-thickness burn eschar, collagenase alone may simply be too slow. Where collagenase holds its ground is in partial-thickness burns managed over days to weeks, especially in settings where a one-time rapid debridement is not practical or available.
Collagenase Versus Autolytic Debridement
The main alternative to enzymatic debridement in many wound care settings is autolytic debridement, which relies on the body’s own enzymes and moisture. A hydrogel or moisture-retentive dressing is placed over the wound, and over time, the body’s white blood cells and enzymes slowly liquefy the dead tissue. It is the gentlest approach, but also the slowest.
A systematic review comparing the two found that enzymatic debridement produced faster wound-size reduction in most studies, with complete healing in about 65% of enzymatic-debridement cases versus 50% for autolytic methods. Granulation tissue, the pink, granular tissue that signals active healing, formed more quickly in the enzymatic group. The reviewers noted that enzymatic debridement proved superior for more severe wounds, while autolytic debridement remains a reasonable choice for less severe cases because of its noninvasive nature. Mild local irritation was the most common side effect reported with the enzyme.12PubMed Central. Comparative Efficacy of Autolytic and Collagenase‐Based Enzymatic Debridement in Chronic Wound Healing: A Comprehensive Systematic Review
An economic model for pressure ulcers found stark cost differences. Patients treated with collagenase had an expected healing time of about 48 wound-days, compared to 147 wound-days for those receiving hydrogel autolytic debridement. The estimated direct cost per patient was roughly $2,000 for collagenase versus $5,500 for the hydrogel approach, making collagenase about four times more cost-effective per healed wound day.13PubMed. Clinical and economic benefit of enzymatic debridement of pressure ulcers compared to autolytic debridement with a hydrogel dressing The ointment itself is not cheap, but when you factor in the shorter treatment duration, fewer dressing changes, and fewer complications, the total bill tends to come out lower.
What You Cover It With Matters
Because collagenase is an enzyme, it can be deactivated by certain chemicals, and the choice of secondary dressing is not arbitrary. Laboratory testing of various dressings used over collagenase found that some common wound dressings are compatible while others are not. Polyvinyl alcohol dressings and collagen dressings maintained the enzyme’s activity, but iodine-containing dressings inhibited it. A nanocrystalline silver dressing caused more than 50% loss of collagenase activity.14Advances in Skin & Wound Care. The Effect of Various Wound Dressings on the Activity of Debriding Enzymes
A systematic review added further detail. Ionic silver dressings produced minimal interference with collagenase, but metallic silver dressings reduced activity by more than half. Cadexomer iodine was even worse, inhibiting collagenase activity by roughly 90%. Solutions with a pH below 6 or above 8, including some antiseptic cleansers containing heavy metal ions, acetic acid, or hypochlorite, also reduce the enzyme’s ability to work. If any of these products have been applied to the wound, the wound bed should be rinsed with saline before the collagenase is applied.15Journal of Wound, Ostomy, and Continence Nursing. Collagenase for Enzymatic Debridement: A Systematic Review
This is one of the more underappreciated pitfalls in wound care. A clinician or home caregiver might apply collagenase diligently and then cover it with an iodine dressing, effectively neutralizing the enzyme they just put on. If you are using collagenase at home and the wound does not seem to be responding, it is worth checking whether the secondary dressing or any wound cleanser could be the problem.
Cost-Effectiveness in Pressure Ulcers
Chronic wounds are expensive to treat, and most of the cost comes not from the dressing or ointment itself but from the nursing time, supplies, and complications over the weeks or months it takes to heal. Several economic analyses have examined whether collagenase saves money compared to alternatives, and the answer has been fairly consistent for pressure injuries.
Compared to medicinal honey, another commonly used wound product, a one-year economic model found that collagenase was simultaneously more effective and less costly. Patients treated with collagenase accumulated slightly more quality-adjusted time at a cost of about $6,200 over the year, versus about $7,100 for medicinal honey.16PubMed Central. Economic analysis and budget impact of clostridial collagenase ointment compared with medicinal honey for treatment of pressure ulcers in the US A separate analysis focused on Stage IV pressure ulcers, the deepest and most serious kind, found that adding collagenase to standard debridement yielded about 17 additional ulcer-free weeks over two years while saving roughly $6,400 per patient compared to debridement without the enzyme. For every additional ulcer-free week gained, the concurrent saving was about $375.17PubMed. Cost effectiveness of adding clostridial collagenase ointment to selective debridement in individuals with stage IV pressure ulcers
These numbers come from economic models rather than direct cost-tracking in a single trial, so they should be taken as estimates. Still, the pattern across multiple analyses points in the same direction: faster debridement leads to faster healing, which leads to fewer dressing changes, fewer infections, fewer emergency visits, and lower total costs.
Use in Neonates and Infants
Wound care in very young patients raises unique concerns. Neonates and infants in intensive care units can develop wounds from IV infiltration, surgical sites, or pressure from medical devices, and these wounds sometimes stall with necrotic tissue that needs removal. Surgical debridement in a baby weighing a few pounds carries obvious risks, and many clinicians prefer gentler approaches.
A retrospective case series from a neonatal intensive care unit found that collagenase was safe and effective for debridement of non-healing and necrotic wounds in infants and neonates. Once collagenase was started, wounds that had been stuck under prior therapy reached full granulation in 5 to 18 days, with an average of about 12 days. Surgical intervention was not required for any of the wounds, and daily wound care was completed with negligible pain recordings.18PubMed Central. Collagenase for Wound Debridement in the Neonatal Intensive Care Unit: A retrospective case series This is a small case series, not a large trial, but the absence of adverse events and the avoidance of surgery in a fragile population is encouraging and aligns with the enzyme’s generally mild safety profile in other settings.
When Collagenase Is Not the Right Choice
Collagenase works best on wounds with moderate amounts of necrotic tissue, particularly slough or thin eschar. Thick, hard, dry eschar responds poorly unless cross-hatched first, and even then, very thick wounds may need mechanical or surgical debridement to get things started before enzymatic treatment can finish the job. In wounds that are heavily infected, controlling the infection typically takes priority, and collagenase alone is not an antimicrobial agent. It can be used alongside antibiotics, and the systematic evidence supports this combination in burn care, but it should not be used as a substitute for addressing active infection.19PubMed Central. Enzymatic debridement with collagenase in wounds and ulcers: a systematic review and meta-analysis
Clean wounds with healthy granulation tissue do not need debridement at all, and applying collagenase to them would not help and could irritate the new tissue. The enzyme is a tool for removing dead material and preparing the wound bed, not a general healing accelerator to be smeared on any open wound. Once the wound bed is clean, pink, and granulating, collagenase should be stopped and a standard moisture-retentive dressing or advanced wound therapy takes over.
The Broader Landscape of Enzymatic Debridement
Collagenase derived from Clostridium histolyticum has been the dominant enzymatic debriding agent in the United States for decades, partly because it is the only one with FDA approval for wound debridement. But it is not the only enzyme that can do this work. Bromelain-based products, as noted earlier in the burn comparison, can debride much faster and are gaining regulatory approvals outside the U.S. Papain-urea combinations were once widely used in the American market but were removed by the FDA in 2008 for being marketed without approved applications.
Researchers are also exploring how proteases beyond collagenase might target wound biofilms, the sticky microbial communities that form on chronic wounds and resist both the immune system and topical antibiotics. Collagenase targets collagen specifically, but biofilms are built from a mix of proteins, polysaccharides, and DNA, so broader-spectrum protease combinations may eventually prove more effective at disrupting them. For now, collagenase remains the most accessible and best-studied enzymatic debridement option in wound care, with the strongest evidence base in pressure ulcers and diabetic foot ulcers and a growing body of data in burns and neonatal wounds.